Shane Cooke Sold 20000 Shares of Alkermes Plc (ALKS) Shares

Cornelia Mascio
Aprile 17, 2018

If the $38.03 PT is reached, the company will be worth $132.66M more. Alpha Beta Stock (ABS) makes sure to keep the information up to date and correct, but we didn't suggest or recommend buying or selling of any financial instrument unless that information is subsequently confirmed on your own. About 525,572 shares traded or 0.95% up from the average. At Home Group Inc. It has outperformed by 22.31% the S&P500.

Shares in Irish biopharma group Alkermes jumped sharply after the United States Food and Drug Administration (FDA) agreed to reconsider a depression drug it had snubbed only two weeks ago. Therefore 61% are positive. Premier had 42 analyst reports since August 25, 2015 according to SRatingsIntel.

Shares of Alkermes stock opened at $58.28 on Friday. The company was maintained on Friday, October 20 by Mizuho. On Thursday, June 29 the stock rating was maintained by J.P. Morgan with "Buy".

Kelly Lawrence W & Associates Inc decreased its stake in Alkermes Plc Shs (ALKS) by 99.06% based on its latest 2017Q4 regulatory filing with the SEC. Along recent fall drift, stock price presented -40.28% down comparing value from it 52-week high point and showed 3.35% up in value from its 52-week low point. As per Wednesday, October 7, the company rating was maintained by Barclays Capital. The company was initiated on Thursday, May 26 by Evercore. The firm has "Outperform" rating given on Thursday, January 21 by Leerink Swann. The stock has "Overweight" rating by Barclays Capital on Wednesday, October 7. As per Friday, October 21, the company rating was upgraded by JP Morgan.

Investors sentiment decreased to 0.75 in 2017 Q4. It's down -0.29, from 1.04 in 2017Q3. Cubist Systematic Strategies Ltd Liability Com invested 0.01% in Alkermes plc (NASDAQ:ALKS). BlackRock Fund Advisors raised its stake in Alkermes Plc by 3.2% in the third quarter. The hedge funds in our database now possess: 152.34 million shares, up from 144.69 million shares in 2017Q3. ORDINARY SHARES A's float is 0.01%.

Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products that are created to address unmet medical needs of patients in various therapeutic areas worldwide. TheStreet raised Alkermes Plc from a "d+" rating to a "c" rating in a report on Wednesday, February 15th. Bailard Inc. acquired a new stake in shares of Alkermes in the fourth quarter worth about $274,000. Gateway Investment Advisers Limited Liability reported 0.08% stake. AMP Capital Investors Ltd now owns 53,745 shares of the company's stock worth $2,732,000 after buying an additional 5,306 shares during the last quarter. The Massachusetts-based Panagora Asset Mgmt has invested 0% in Alkermes plc (NASDAQ:ALKS). Asset Management One Commerce holds 0.03% or 221,743 shares in its portfolio. The Return on Assets for Alkermes plc (NasdaqGS:ALKS) is -0.091487. Commercial Bank Of Montreal Can owns 13,194 shares or 0% of their USA portfolio. Raymond James And invested 0% of its portfolio in Alkermes plc (NASDAQ:ALKS). Alkermes plc traded 692340 shares at hands versus to its average volume of 1192.69K shares. The overall volume in the last trading session was 3,433,544 shares. About 567,628 shares traded. Alkermes plc (NASDAQ:ALKS) has declined 0.51% since April 16, 2017 and is downtrending. It has underperformed by 11.55% the S&P500.

Alkermes plc is a biopharmaceutical company. The stock has a market cap of $8,975.64, a price-to-earnings ratio of -56.58 and a beta of 1.87. The companyÂ's marketed products include ARISTADA for the treatment of schizophrenia; VIVITROL (naltrexone for extended-release injectable suspension) for the treatment of alcohol and opioid dependence; RISPERDAL CONSTA for the treatment of schizophrenia and bipolar I disorder; INVEGA SUSTENNA for the treatment of schizophrenia and schizoaffective disorder; XEPLION, INVEGA TRINZA, and TREVICTA for treating schizophrenia; AMPYRA (dalfampridine)/FAMPYRA (fampridine) to enhance walking in adults with multiple sclerosis who have walking disability; and BYDUREON (exenatide extended-release for injectable suspension) for the treatment of type 2 diabetes. It now has negative earnings. Specifically, the FDA accepted for review the New Drug Application (NDA) for ALKS 5461 for the adjunctive treatment of major depressive disorder in patients with an inadequate response to standard antidepressant therapies.

The Piotroski F-Score is a scoring system between 1-9 that determines a firm's financial strength. It has a 71.76 P/E ratio.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.

Altre relazioniGrafFiotech

Discuti questo articolo

Segui i nostri GIORNALE